scholarly journals Exacerbation of COVID 19 in Hypertensive Patients ( A review)

2021 ◽  
Vol 30 (2) ◽  
pp. 23-30
Author(s):  
Noor Hatef Naser ◽  
Ammar Abdul Aziz Alibeg
Keyword(s):  
Blood Pressure ◽  
Risk Factor ◽  
Acute Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Epidemiological Studies ◽  
Rapid Rate ◽  
Converting Enzyme ◽  
Antihypertensive Medications ◽  
Hypertensive Patients ◽  
Angiotensin Converting Enzyme 2

Since its discovery in December 2019, corona virus was outbreak worldwide with very rapid rate, so it described by WHO as pandemic. It associated with severe acute respiratory distress syndrome, and can enter to cells through Angiotensin Converting Enzyme 2 (ACE 2) receptor which play an important role as regulator for blood pressure. Hypertension is a potential risk factor for sever acute respiratory syndrome COVID-19, and associated with high mortality rate as shown in many epidemiological studies. Moreover, specific antihypertensive medications that infected patients were receiving are not known; only data about renin-angiotensin-aldosterone system (RAAS) are available.  

scholarly journals Hyperglycemia and Angiotensin-Converting Enzyme 2 in Pulmonary Function in the Context of SARS-CoV-2 Infection

2022 ◽  
Vol 8 ◽  
Author(s):  
Jose R. Vargas-Rodriguez ◽  
Idalia Garza-Veloz ◽  
Virginia Flores-Morales ◽  
Jose I. Badillo-Almaraz ◽  
Maria R. Rocha-Pizaña ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Acute Respiratory Distress Syndrome ◽  
Severe Acute Respiratory Syndrome ◽  
Angiotensin Converting Enzyme ◽  
Distress Syndrome ◽  
Current Evidence ◽  
Pathophysiological Mechanism ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Worse Prognosis

Since the appearance of the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 in China, diabetes mellitus (DM) and hyperglycemia in patients infected with SARS-CoV, represent independent predictors of mortality. Therefore, metabolic control has played a major role in the prognosis of these patients. In the current pandemic of coronavirus disease 19 (COVID-19), multiple studies have shown that DM is one of the main comorbidities associated with COVID-19 and higher risk of complications and death. The incidence and prevalence of COVID-19 complications and death related with hyperglycemia in patients with or without DM are high. There are many hypotheses related with worse prognosis and death related to COVID-19 and/or hyperglycemia. However, the information about the interplay between hyperglycemia and angiotensin-converting enzyme 2 (ACE2), the critical receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in the context of SARS-CoV-2 infection, is almost null, but there is enough information to consider the possible participation of hyperglycemia in the glycation of this protein, unleashing a pool of reactions leading to acute respiratory distress syndrome and death in patients with COVID-19. In this document we investigated the current evidence related with ACE2 as a key element within the pathophysiological mechanism related with hyperglycemia extrapolating it to context of SARS-CoV-2 infection and its relationship with worse prognosis and death for COVID-19.

scholarly journals Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients

eLife ◽  
2020 ◽  
Vol 9 ◽  
Author(s):  
Gian Paolo Rossi ◽  
Viola Sanga ◽  
Matthias Barton
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Angiotensin Converting Enzyme ◽  
Distress Syndrome ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Mas Receptor ◽  
Pulmonary Protection ◽  
Therapeutic Considerations ◽  
Harmful Effects

The discovery of angiotensin converting enzyme-2 (ACE-2) as the receptor for SARS- CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) has implicated the renin-angiotensin-aldosterone system in acute respiratory distress syndrome (ARDS) and respiratory failure in patients with coronavirus disease-19 (COVID-19). The angiotensin converting enzyme-1–angiotensin II–angiotensin AT1 receptor pathway contributes to the pathophysiology of ARDS, whereas activation of the ACE-2–angiotensin(1-7)-angiotensin AT2 receptor and the ACE-2–angiotensin(1-7)–Mas receptor pathways have been shown to be protective. Here we propose and discuss therapeutic considerations how to increase soluble ACE-2 in plasma in order for ACE-2 to capture and thereby inactivate SARS-CoV-2. This could be achieved by administering recombinant soluble ACE-2. We also discuss why and how ACEIs and ARBs provide cardiovascular, renal and also pulmonary protection in SARS-CoV-2- associated ARDS. Discontinuing these medications in COVID-19 patients may therefore potentially be harmful.

Risk factor analysis of postoperative acute respiratory distress syndrome in valvular heart surgery

2016 ◽  
Vol 31 (1) ◽  
pp. 139-143 ◽  
Author(s):  
Shao-Wei Chen ◽  
Chih-Hsiang Chang ◽  
Pao-Hsien Chu ◽  
Tien-Hsing Chen ◽  
Victor Chien-Chia Wu ◽  
...  
Keyword(s):  
Factor Analysis ◽  
Risk Factor ◽  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Heart Surgery ◽  
Distress Syndrome ◽  
Risk Factor Analysis

Cytomegalovirus Seroprevalence as a Risk Factor for Poor Outcome in Acute Respiratory Distress Syndrome*

2015 ◽  
Vol 43 (2) ◽  
pp. 394-400 ◽  
Author(s):  
David S. Y. Ong ◽  
Peter M. C. Klein Klouwenberg ◽  
Frans M. Verduyn Lunel ◽  
Cristian Spitoni ◽  
Jos F. Frencken ◽  
...  
Keyword(s):  
Risk Factor ◽  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Poor Outcome
Sign in / Sign up

Export Citation Format

Share Document